Is GeneDx Holdings (NASDAQ:WGS) A Risky Investment?
Is GeneDx Holdings (NASDAQ:WGS) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' So it might be obvious that you need to consider debt, when you think about how risky any given stock is, because too much debt can sink a company. Importantly, GeneDx Holdings Corp. (NASDAQ:WGS) does carry debt. But is this debt a concern to shareholders?
伯克希尔哈撒韦的慈善·芒格支持的对外基金管理人李录在说到“最大的投资风险不是价格波动,而是你是否会遭受永久性的资本损失”时毫不掩饰地点出了这一点。因此,当你考虑一只股票的风险性时,需要考虑债务,因为过多的债务会让一家公司陷入困境。重要的是,GeneDx Holdings Corp. (NASDAQ:WGS) 确实有负债。但是这些债务会引起股东的担忧吗?
When Is Debt A Problem?
什么时候负债才是一个问题?
Debt and other liabilities become risky for a business when it cannot easily fulfill those obligations, either with free cash flow or by raising capital at an attractive price. Ultimately, if the company can't fulfill its legal obligations to repay debt, shareholders could walk away with nothing. However, a more usual (but still expensive) situation is where a company must dilute shareholders at a cheap share price simply to get debt under control. Of course, plenty of companies use debt to fund growth, without any negative consequences. The first step when considering a company's debt levels is to consider its cash and debt together.
当企业不能轻松通过自由现金流或以有吸引力的价格筹集资本来满足偿还债务的义务时,债务和其他负债会对企业产生风险。 如果公司无法履行偿还债务的法律义务,股东可能一无所获。 然而,更常见(但仍然不便宜)的情况是,公司必须以低廉的股票价格稀释股东,以控制债务。 当然,许多公司使用债务来资助业务增长,没有产生任何负面后果。 在考虑公司的债务水平时,第一步是考虑其现金和债务的总体情况。
What Is GeneDx Holdings's Debt?
GeneDx Holdings的债务情况是怎样的?
You can click the graphic below for the historical numbers, but it shows that as of June 2024 GeneDx Holdings had US$52.2m of debt, an increase on US$6.25m, over one year. However, it does have US$106.9m in cash offsetting this, leading to net cash of US$54.7m.
你可以点击下面的图表查看历史数据。但是数据显示在2024年6月,GeneDx Holdings的债务为5220万美元,比一年前625万美元增加。然而,它有1.069亿美元现金来抵消这些债务,因此净现金为5470万美元。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240820/0-9b11befb22ec8c422b624468ff60bde3-0-8deba46aba0d9f9752f4d16bd709361b.png/big)
A Look At GeneDx Holdings' Liabilities
GeneDx Holdings的负债情况
The latest balance sheet data shows that GeneDx Holdings had liabilities of US$68.3m due within a year, and liabilities of US$126.8m falling due after that. On the other hand, it had cash of US$106.9m and US$26.2m worth of receivables due within a year. So it has liabilities totalling US$62.0m more than its cash and near-term receivables, combined.
最新的资产负债表数据显示,GeneDx Holdings今年有6830万美元的短期债务,之后的债务为12680万美元,另外还有10690万美元现金和2620万美元即将在短期内到期的应收账款。因此,其负债合计比现金和短期应收账款还差6200万美元。由于公开交易的 GeneDx Holdings 股价合计为 9,3120 万美元,因此这种程度的负债似乎不会构成重大威胁。话虽如此,很明显,我们应该继续关注它的资产负债表,以防发生不利变化。尽管有引人注目的负债,GeneDx Holdings 仍然拥有净现金,因此可以说其债务负担不重!当你分析债务时,资产负债表显然是需要关注的领域。但最终企业的未来盈利能力将决定 GeneDx Holdings 是否能够随着时间的推移加强其资产负债表。因此,如果你关注未来,可以查看这份免费报告,其中显示了分析师的利润预测。
Since publicly traded GeneDx Holdings shares are worth a total of US$931.2m, it seems unlikely that this level of liabilities would be a major threat. Having said that, it's clear that we should continue to monitor its balance sheet, lest it change for the worse. Despite its noteworthy liabilities, GeneDx Holdings boasts net cash, so it's fair to say it does not have a heavy debt load! The balance sheet is clearly the area to focus on when you are analysing debt. But ultimately the future profitability of the business will decide if GeneDx Holdings can strengthen its balance sheet over time. So if you're focused on the future you can check out this free report showing analyst profit forecasts.
在过去的一年中,GeneDx Holdings在EBIT水平上没有盈利,但却成功将收入增长了3.1%,达到了2.44亿美元。我们对这种增长率持谨慎态度,毕竟这取决于具体情况。因此,GeneDx Holdings到底有多大的风险呢?毫无疑问,产生亏损的公司一般而言比盈利的公司更具风险性。我们注意到 GeneDx Holdings 在过去一年里录得了利息、所得税前利润(EBIT)亏损,并且在那段时间里烧掉了9600万美元的现金,亏损达到了11700万美元。但至少它在资产负债表上有5470万美元的净现金用于未来的增长。总体而言,我们认为该股票存在一定的风险,在看到正面的自由现金流之前都应非常谨慎。从资产负债表中可以了解债务的大部分情况。但是,投资风险并不完全来自于资产负债表。请注意 GeneDx Holdings 在我们的投资分析中显示了4个警告信号,其中至少有1个不应被忽视......
In the last year GeneDx Holdings wasn't profitable at an EBIT level, but managed to grow its revenue by 3.1%, to US$244m. That rate of growth is a bit slow for our taste, but it takes all types to make a world.
在过去的一年中,GeneDx Holdings在EBIT水平上没有盈利,但却成功将收入增长了3.1%,达到了2.44亿美元。我们对这种增长率持谨慎态度,毕竟这取决于具体情况。
So How Risky Is GeneDx Holdings?
GeneDx Holdings存在多大的风险?
We have no doubt that loss making companies are, in general, riskier than profitable ones. And we do note that GeneDx Holdings had an earnings before interest and tax (EBIT) loss, over the last year. Indeed, in that time it burnt through US$96m of cash and made a loss of US$117m. But at least it has US$54.7m on the balance sheet to spend on growth, near-term. Overall, we'd say the stock is a bit risky, and we're usually very cautious until we see positive free cash flow. There's no doubt that we learn most about debt from the balance sheet. However, not all investment risk resides within the balance sheet - far from it. Be aware that GeneDx Holdings is showing 4 warning signs in our investment analysis , and 1 of those shouldn't be ignored...
我们毫不怀疑,总的来说,亏损的公司比盈利的公司更具风险性。我们注意到 GeneDx Holdings 在过去一年里录得了利息、所得税前利润(EBIT)亏损,并且在那段时间里烧掉了9600万美元的现金,亏损达到了11700万美元。但至少它在资产负债表上有5470万美元的净现金用于未来的增长。总体而言,我们认为该股票存在一定的风险,在看到正面的自由现金流之前都应非常谨慎。从资产负债表中可以了解债务的大部分情况。但是,投资风险并不完全来自于资产负债表。请注意,GeneDx Holdings 在我们的投资分析中显示了4个警告信号,其中至少有1个不应被忽视......
If you're interested in investing in businesses that can grow profits without the burden of debt, then check out this free list of growing businesses that have net cash on the balance sheet.
如果您有兴趣投资能够在不负债的情况下增长利润的企业,请查看这份免费列表,其中列出了在资产负债表上拥有净现金的成长型企业。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。